Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk
Project factsheets
The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.
Displaying 84 projects/programmes
Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes
Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
Accelerated development of vaccine benefit-risk collaboration in Europe
Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy
Applied public-private research enabling osteoarthritis clinical headway
Biomarkers for Enhanced Vaccine Immunosafety
Be The Cure
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
Chemical manufacturing methods for the 21st century pharmaceutical industries
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets
Drug Disease Model Resources
Diabetes research on patient stratification
Big data for better outcomes, policy innovation and healthcare system transformation
Driving re-investment in R&D and responsible antibiotic use
European Bank for induced pluripotent Stem Cells
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment
Ebola virus: modern approaches for developing bedside rapid diagnostics
Manufacturing and development for rapid access Ebola vaccine
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II
Ensuring the future of EUPATI beyond 2020
Electronic Health Records Systems for Clinical Research
European Lead Factory
European Medical Information Framework
European Medicines Research Training Network
European Gram-negative Antibacterial Engine
European prevention of Alzheimer’s dementia consortium
European Quality In Preclinical Data
Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities
Delivering European Translational Information & Knowledge Management Services
European Autism Interventions - a Multicentre Study for Developing New Medications
European programme in Pharmacovigilance and Pharmacoepidemiology
European Patients' Academy on Therapeutic Innovation
Understanding chronic pain and improving its treatment
Ultra-fast molecular filovirus diagnostics
Standardization and development of assays for assessment of influenza vaccines correlates of protection
Incorporating real-life clinical data into drug development
The GetReal Initiative
Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
Inhibiting misfolded protein propagation in neurodegenerative diseases
Intelligent Assessment of Pharmaceuticals in the Environment
Kinetics for Drug Discovery
Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury
Mobile Filovirus Nucleic Acid Test
Models of patient engagement for Alzheimer’s disease
Efficiently networking European neurodegeneration research
Novel methods leading to new medications in depression and schizophrenia
Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments
Methods for systematic next generation oncology biomarker development
The Open Pharmacological Concepts Triple Store
Oral biopharmaceutics tools
Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes
Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
Pan Ebola vaccine innovative approach
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
Pharmaceutical Medicine Training Programme
Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases
New models for preclinical evaluation of drug efficacy in common solid tumours
Model-based preclinical development of anti-tuberculosis drug combinations
Patient Preferences in benefit risk assessments during the drug life cycle
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
Physical Activity as a Crucial Patient Reported Outcome in COPD
Pharmacoepidemiological research on outcomes of therapeutics by a European consortium
Quantative imaging in cancer:connecting cellular process with therapy
Development of rapid point-of-care test platforms for infectious diseases
Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
Real world outcomes across the AD spectrum for better care: multi-modal data access platform
Safer and Faster Evidence-based Translation
European Modular Education and Training Programme in Safety Sciences for Medicines
Sarcopenia and physical frailty in older people: multi‐component treatment strategies
Stem cells for biological assays of novel drugs and predictive toxicology
Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
Molecular basis of the bacterial cell wall permeability
Translational quantitative systems toxicology to improve the understanding of the safety of medicines
Unbiased biomarkers for the prediction of respiratory disease outcomes
Unrestricted leveraging of targets for research advancement and drug discovery
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
Recognising Adverse Drug Reactions
WEB-RADR 2
Zoonotic anticipation and preparedness initiative
